7.22 0.00 (0.00%)
After hours: 4:39PM EDT
|Bid||6.50 x 27000|
|Ask||7.34 x 800|
|Day's range||7.11 - 7.28|
|52-week range||4.31 - 11.27|
|PE ratio (TTM)||N/A|
|Earnings date||6 Aug 2018 - 10 Aug 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||8.67|
Depomed, Inc. (DEPO) announced that the Company will grant Phillip B. Donenberg, the Company’s new Chief Financial Officer and Senior Vice President, 87,163 restricted stock units (“RSUs”) and 87,163 target performance stock units (“PSUs”), in each case effective upon the commencement of his employment with the Company on July 16, 2018. The RSUs and PSUs will be granted as inducements material to Mr. Donenberg’s entry into employment with Depomed in accordance with NASDAQ Listing Rule 5635(c)(4). The RSUs and PSUs will be subject to Mr. Donenberg’s continued service relationship with the Company, and to the terms and conditions of the Company's 2014 Omnibus Incentive Plan and the award agreements pursuant to which they were granted.
Lake Forest, Illinois, June 5, 2018 - Depomed, Inc. (DEPO) today announced that it has appointed Phillip B. Donenberg as Chief Financial Officer and Senior Vice President, effective July 16, 2018. Mr. Donenberg will succeed August J. Moretti who has served as Depomed’s Chief Financial Officer since January 2012. "Phil brings exceptional finance experience and a proven track record of success, most recently as CFO of AveXis," said Arthur Higgins, President and Chief Executive Officer of Depomed.
The Newark, California-based company said it had net income of 48 cents per share. Earnings, adjusted for non-recurring gains, were 28 cents per share. The results topped Wall Street expectations. The ...
-Company Confirms Previous 2018 Guidance for Neurology Franchise Net Sales and Non-GAAP Adjusted EBITDA-. -Amends Existing Agreement for CAMBIA Line Extension–. -Announces New Co-Promotion Agreement for ...
LAKE FOREST, Ill., May 07, 2018-- Depomed, Inc. today announced that members of senior management will participate at the 2018 UBS Global Healthcare Conference in a session scheduled for 1:30 pm ET on ...
Depomed, Inc. (DEPO) today announced that it will release first-quarter 2018 financial results on Thursday, May 10, 2018, before the open of markets. Following the announcement, the Company will host a conference call beginning at 8:30 a.m. ET to discuss its results. Participants can access the live webcast from the Investor Relations section of Depomed's website at http://www.depomed.com.
Depomed, Inc. (DEPO) today announced the appointment of John B. Thomas as Senior Vice President, Investor Relations and Corporate Communications, effective immediately. Mr. Thomas most recently served as Executive Vice President, Corporate Strategy and Investor Relations at Horizon Pharma.
NEW YORK, April 16, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
NEWARK, Calif., April 09, 2018-- Depomed, Inc. made a grant on April 2, 2018 of 91,324 restricted stock units and 91,324 target performance stock units to Stan Bukofzer, M.D., the Company’ s newly appointed ...
NEWARK, Calif., April 02, 2018-- Depomed, Inc. today announced the appointment of Stan Bukofzer, M.D., as Senior Vice President, Chief Medical and Scientific Officer, effective immediately. Bukofzer most ...
President Donald Trump said he's considering suing drugmakers for their role in fueling the opioid epidemic, sending pharma stocks tumbling.
Collegium touched a buy zone Thursday after sales of painkiller Xtampza easily beat Street expectations in the fourth quarter.
In fiscal 2017, Depomed (DEPO) generated total revenues of $380.7 million. Of these total revenues, $379.8 million came from product sales, and ~$844,000 came from royalties. By comparison, the company had generated total revenues of $455.8 million in fiscal 2016, of which $455 million came from product sales and $831 million from royalties.
Depomed (DEPO) generates a major part of its sales from five major products: Nucynta, Gralise, Cambia, Lazanda, and Zipsor. Sales of products in Depomed’s Nucynta franchise fell from $281.2 million in fiscal 2016 to $239.5 million in fiscal 2017. Depomed acquired the Nucynta franchise from Janssen in April 2015.
Depomed (DEPO) has adopted a three-pronged business strategy with three key elements: maintain, build, and grow. Depomed aims to maintain its Nucynta franchise of pain products through the commercialization agreement it entered into with Collegium Pharmaceutical in December 2017. Under this agreement, Depomed granted commercialization rights for the Nucynta franchise of pain products to Collegium Pharmaceutical in the US.
Depomed (DEPO) is a specialty pharmaceutical company with a focus on pain and CNS (central nervous system) conditions. In March 2018, two of the seven analysts covering Depomed have given the stock a “buy” rating. By comparison, of the 22 analysts covering Merck (MRK) in March 2018, six analysts have given the stock a “strong buy” rating, and seven analysts have given it a “buy” rating, while nine analysts have given it a “hold” rating.
On a per-share basis, the Newark, California-based company said it had a loss of 52 cents. Earnings, adjusted for non-recurring costs and pretax expenses, were 15 cents per share. The results beat Wall ...